$22.81 -0.14 (%) Aegerion Pharmaceuticals Inc - NASDAQ

Dec. 19, 2014 | 04:00 PM

Partner Headlines

  1. Gilead Sciences Releases Impressive Results for Hepatitis C Drug

    GuruFocus | Nov. 12, 2014 | 11:56AM EST
  2. The Future Of Aegerion Pharmaceutical's Stock

    Benzinga | Nov. 3, 2014 | 18:13PM EST
  3. Meet The Biopharma Stock That Lost 34% Last Week

    Benzinga | Nov. 3, 2014 | 18:13PM EST
  4. Midday Losers From October 31: Aegerion Pharmaceuticals, Bottomline Technologies, Digital Globe

    Benzinga | Oct. 31, 2014 | 13:38PM EST
  5. Mid-Day Market Update: GoPro Jumps On Upbeat Results; Tempur Sealy Shares Dip

    Benzinga | Oct. 31, 2014 | 13:34PM EST
  6. Mid-Morning Market Update: Markets Open Higher; Clorox Earnings Top Street View

    Benzinga | Oct. 31, 2014 | 11:06AM EST
  7. Morning Market Losers

    Benzinga | Oct. 31, 2014 | 10:08AM EST
  8. Benzinga's Top Downgrades

    Benzinga | Oct. 31, 2014 | 08:55AM EST
  9. Benzinga's Top #PreMarket Losers

    Benzinga | Oct. 31, 2014 | 08:21AM EST
  10. Jefferies Downgrades Aegerion Pharmaceuticals To Hold

    Benzinga | Oct. 31, 2014 | 07:54AM EST
  11. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  12. Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

    Benzinga | Oct. 8, 2014 | 16:06PM EST
  13. Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

    Benzinga | Sep. 9, 2014 | 08:07AM EST
  14. Aegerion Pharmaceuticals Announces Resolution Of Warning Letter for JUXTAPID (lomitapide) Capsules

    Benzinga | Aug. 27, 2014 | 07:06AM EST
  15. Markets Open Higher; Priceline Issues Downbeat Profit Forecast

    Benzinga | Aug. 11, 2014 | 11:32AM EST
  16. US Stock Futures Signal Higher Start On Wall Street

    Benzinga | Aug. 11, 2014 | 07:44AM EST
  17. Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR

    GuruFocus | Aug. 4, 2014 | 11:11AM EST
  18. The FED Continues To Taper; Indices Rebound Slightly

    Benzinga | Jul. 30, 2014 | 15:07PM EST
  19. Twitter Jumps On Upbeat Results; DreamWorks Shares Slide

    Benzinga | Jul. 30, 2014 | 12:47PM EST
  20. Markets Mixed; Sprint Posts Profit

    Benzinga | Jul. 30, 2014 | 11:29AM EST
  21. Benzinga's Volume Movers

    Benzinga | Jul. 30, 2014 | 10:50AM EST
  22. Morning Market Movers

    Benzinga | Jul. 30, 2014 | 09:46AM EST
  23. Benzinga's Top #PreMarket Gainers

    Benzinga | Jul. 30, 2014 | 08:06AM EST
  24. Stocks Hitting 52-Week Lows

    Benzinga | Jul. 18, 2014 | 13:19PM EST
  25. 5-Star Biotech Stock Watch: Aegerion Pharmaceuticals

    Benzinga | Jul. 9, 2014 | 15:30PM EST
  26. Stocks Hitting 52-Week Lows

    Benzinga | Jul. 9, 2014 | 10:16AM EST
  27. Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS

    GuruFocus | Jun. 2, 2014 | 11:45AM EST
  28. Four CEOs Reporting Large Insider Buys

    GuruFocus | May. 9, 2014 | 19:29PM EST
  29. Morning Market Losers

    Benzinga | May. 7, 2014 | 09:48AM EST
  30. UPDATE: Aegerion Pharma Commences Phase 3 Clinical Trial in Japan, Will Evaluate Lomitapipde for Treatment of HoFH

    Benzinga | Apr. 9, 2014 | 08:07AM EST
  31. Aegerion's JUXTAPID Capsules Approved in Mexico for Treatment of Homozygous Familial Hypercholesterolemia

    Benzinga | Jan. 20, 2014 | 08:10AM EST
  32. Leerink Swann Reiterates on Aegerion Pharmaceuticals as Weakness is Overdone

    Benzinga | Nov. 19, 2013 | 11:26AM EST
  33. Canaccord Genuity Reiterates on Aegerion Pharmaceuticals as Selling is Overdone

    Benzinga | Nov. 19, 2013 | 10:50AM EST
  34. Aegerion Pharmaceuticals Presents Data From Phase 3 Extension Study of JUXTAPID(TM) (lomitapide) Capsules in Homozygous Familial Hypercholesterolemia (HoFH) at AHA Scientific Sessions

    Benzinga | Nov. 18, 2013 | 16:04PM EST
  35. UPDATE: Deutsche Bank Reiterates on Aegerion Pharmaceuticals Following Company Analyst Day

    Benzinga | Nov. 13, 2013 | 10:23AM EST
  36. Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies Dominate Headlines

    Benzinga | Nov. 8, 2013 | 16:57PM EST
  37. Benzinga's Top Pre-Market Gainers

    Benzinga | Jul. 30, 2013 | 08:12AM EST
  38. $176,000 or $295,00 a Year: Bizarre World of Orphan Drugs

    YCharts | Feb. 13, 2013 | 04:32AM EST
  39. Mid-Morning Market Update: Markets Heading Down, Dendreon Rockets Upwards

    Benzinga | Jan. 11, 2013 | 03:49AM EST
  40. UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals

    Benzinga | Jan. 9, 2013 | 05:44AM EST
  41. Aegerion Pharmaceuticals Grants Stock Options to Purchase 55K Shares

    Benzinga | Jan. 4, 2013 | 12:58PM EST
  42. My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List

    GuruFocus | Dec. 27, 2012 | 04:46AM EST
  43. UPDATE: Jefferies Raises PT to $29 on Aegerion Pharmaceuticals on Juxtapid Approval Outlook

    Benzinga | Dec. 27, 2012 | 03:21AM EST
  44. Canaccord Genuity Reiterates Buy Rating, $27 PT on Aegerion Pharmaceuticals

    Benzinga | Dec. 26, 2012 | 01:52AM EST
  45. Stocks To Watch For December 26, 2012

    Benzinga | Dec. 25, 2012 | 19:23PM EST
  46. Aegerion's Juxtapid OK'd

    IBD | Dec. 24, 2012 | 11:38AM EST
  47. UPDATE: J.P. Morgan Reiterates Overweight Rating, Raises PT on Aegerion Pharmaceuticals

    Benzinga | Dec. 24, 2012 | 05:21AM EST
  48. FDA Approves Aegerion's' JUXTAPID Capsules for Homozygous Familial Hypercholesterolemia

    Benzinga | Dec. 24, 2012 | 00:09AM EST
  49. Benzinga's M&A Chatter for Friday December 7, 2012

    Benzinga | Dec. 8, 2012 | 06:17AM EST
  50. Aegerion Pharma Reserves Shares for Inducement Stock Options

    Benzinga | Dec. 6, 2012 | 01:18AM EST
Trading Center